Related Experiment Video

Updated: May 31, 2026

Quantifying the Cytotoxicity of Staphylococcus aureus Against Human Polymorphonuclear Leukocytes
12:27

Quantifying the Cytotoxicity of Staphylococcus aureus Against Human Polymorphonuclear Leukocytes

Published on: January 3, 2020

Synthesis and minimum inhibitory concentrations of SK-03-92 against Staphylococcus aureus and other gram-positive

William R Schwan1, M Shahjahan Kabir, Maren Kallaus

  • 1Department of Microbiology, University of Wisconsin-La Crosse, La Crosse, WI 54601, USA. schwan.will@uwlax.edu

Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy
|July 9, 2011
PubMed

Insights

A novel synthetic drug, SK-03-92, shows broad efficacy against gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). This discovery offers a promising new avenue for treating challenging bacterial infections.

Area of Science:

  • Microbiology
  • Infectious Diseases
  • Drug Discovery

Background:

  • Staphylococcus aureus infections pose a significant public health threat in the US, with thousands of deaths annually.
  • The rise of antibiotic-resistant strains, such as methicillin-resistant Staphylococcus aureus (MRSA) and community-associated MRSA (CA-MRSA), exacerbates this problem.
  • Limited development of new antibiotics and emerging resistance to existing drugs necessitate novel therapeutic strategies.

Purpose of the Study:

  • To identify and evaluate a novel synthetic compound for its efficacy against drug-resistant gram-positive bacteria.
  • To assess the potential of this new drug candidate in combating infections caused by Staphylococcus aureus and other challenging pathogens.

Main Methods:

  • Identification of a novel synthetic compound, designated SK-03-92.
  • In vitro testing of SK-03-92 against a diverse range of gram-positive bacterial strains, including various Staphylococcus aureus isolates.
  • Evaluation of SK-03-92's activity against Mycobacterium strains.

Main Results:

  • SK-03-92 demonstrated broad in vitro efficacy against multiple gram-positive bacterial strains.
  • The compound showed significant activity against numerous strains of Staphylococcus aureus.
  • Additionally, SK-03-92 exhibited activity against Mycobacterium species.

Conclusions:

  • The novel synthetic drug SK-03-92 presents a promising candidate for the treatment of gram-positive bacterial infections, including those caused by MRSA.
  • Its broad-spectrum activity against gram-positive bacteria and Mycobacterium strains warrants further investigation for clinical applications.

More Related Videos

Antimicrobial Synergy Testing by the Inkjet Printer-assisted Automated Checkerboard Array and the Manual Time-kill Method12:03

Antimicrobial Synergy Testing by the Inkjet Printer-assisted Automated Checkerboard Array and the Manual Time-kill Method

Published on: April 18, 2019

A Novel Method to Determine the Longitudinal Antibacterial Activity of Drug-Eluting Materials06:18

A Novel Method to Determine the Longitudinal Antibacterial Activity of Drug-Eluting Materials

Published on: March 3, 2023

Related Concept Videos

Clinical Significance of Antibiotic Resistance01:25

Clinical Significance of Antibiotic Resistance

Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...
Staphylococcal Skin Infections01:29

Staphylococcal Skin Infections

Staphylococcus aureus is a Gram-positive coccus that resides harmlessly on the skin and mucous membranes of healthy individuals. When the skin barrier is breached, it can shift from a commensal to an opportunistic pathogen. This transition is facilitated by surface adhesins, such as clumping factor B and S. aureus surface protein G (SasG), which bind to structural proteins, including loricrin and cytokeratin, in the damaged epidermis. Protein A, another key factor, binds the Fc region of...
Inhibitors of Bacterial Protein Synthesis01:25

Inhibitors of Bacterial Protein Synthesis

Aminoglycosides constitute a highly potent class of bactericidal antibiotics that exert their antimicrobial effects by targeting the bacterial ribosome, specifically disrupting protein synthesis. These polycationic molecules consist of amino-modified sugars linked via glycosidic bonds to an aminocyclitol core such as 2-deoxystreptamine or streptamine. Their strong positive charges facilitate tight binding to the negatively charged phosphate backbone of ribosomal RNA (rRNA), primarily at the 16S...
Inhibitors of Gram-positive Cell Wall Synthesis01:23

Inhibitors of Gram-positive Cell Wall Synthesis

Bacterial cell walls are typically rigid structures composed mainly of peptidoglycan, a mesh-like polymer that provides mechanical strength and maintains cell shape. The synthesis of peptidoglycan is a crucial process in bacterial growth and serves as a primary target for many antibiotics.Mechanism of Action of Beta-Lactam AntibioticsBeta-lactam antibiotics, such as penicillin, inhibit peptidoglycan synthesis in actively growing cells. These antibiotics share a characteristic four-membered...
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...